V von Wyl1, B F Décard2, P Benkert3, J Lorscheider2, P Hänni4, C Lienert5, J Kuhle2, T Derfuss2, L Kappos2, Ö Yaldizli2. 1. Swiss Multiple Sclerosis Registry, Epidemiology, Biostatistics and Prevention Institute, University of Zürich, Zürich, Switzerland. 2. Departments of Medicine, Neurologic Clinic and Policlinic, University Hospital Basel and University of Basel, Basel, Switzerland. 3. Clinical Trial Unit, University Hospital Basel, Basel, Switzerland. 4. Swiss Association for Joint Tasks of Health Insurers, Solothurn, Switzerland. 5. Department of Neurology, Rheinburg Klinik, Walzenhausen, Switzerland.
Abstract
BACKGROUND AND PURPOSE: To investigate the relation of age at disease onset and clinical outcomes across the lifespan from adolescence in patients with multiple sclerosis (MS) on disease-modifying therapy (DMT). METHODS: We analysed data from the Swiss Association for Joint Tasks of Health Insurers database containing data from 14 718 patients with MS. Patients were included in this analysis when they were on DMT for at least 1 year. The influence of age at disease onset on future relapses and disability worsening was explored using multivariable Cox proportional hazard regression models. RESULTS: Data from 9705 patients with MS were analysed. Pediatric-onset MS patients (n = 236) had higher relapse rates and marginally slower disability worsening rates compared with adult-onset MS (n = 9469). The risk of relapses was highest in childhood and decreased continuously to about 35 years of age. It remained stable for about a decade and then again continuously decreased. In contrast, disability worsening hazards remained stable from childhood to about 32 years of age and then increased sharply around the age of 45 years. CONCLUSIONS: Age is an important factor independently affecting clinical outcomes in MS. This should be considered when designing clinical trials or choosing DMT.
BACKGROUND AND PURPOSE: To investigate the relation of age at disease onset and clinical outcomes across the lifespan from adolescence in patients with multiple sclerosis (MS) on disease-modifying therapy (DMT). METHODS: We analysed data from the Swiss Association for Joint Tasks of Health Insurers database containing data from 14 718 patients with MS. Patients were included in this analysis when they were on DMT for at least 1 year. The influence of age at disease onset on future relapses and disability worsening was explored using multivariable Cox proportional hazard regression models. RESULTS: Data from 9705 patients with MS were analysed. Pediatric-onset MSpatients (n = 236) had higher relapse rates and marginally slower disability worsening rates compared with adult-onset MS (n = 9469). The risk of relapses was highest in childhood and decreased continuously to about 35 years of age. It remained stable for about a decade and then again continuously decreased. In contrast, disability worsening hazards remained stable from childhood to about 32 years of age and then increased sharply around the age of 45 years. CONCLUSIONS: Age is an important factor independently affecting clinical outcomes in MS. This should be considered when designing clinical trials or choosing DMT.
Authors: David Pitt; Chih Hung Lo; Susan A Gauthier; Richard A Hickman; Erin Longbrake; Laura M Airas; Yang Mao-Draayer; Claire Riley; Philip Lawrence De Jager; Sarah Wesley; Aaron Boster; Ilir Topalli; Francesca Bagnato; Mohammad Mansoor; Olaf Stuve; Ilya Kister; Daniel Pelletier; Panos Stathopoulos; Ranjan Dutta; Matthew R Lincoln Journal: Neurol Neuroimmunol Neuroinflamm Date: 2022-08-30
Authors: Frank Dahlke; Douglas L Arnold; Piet Aarden; Habib Ganjgahi; Dieter A Häring; Jelena Čuklina; Thomas E Nichols; Stephen Gardiner; Robert Bermel; Heinz Wiendl Journal: Mult Scler Date: 2021-01-28 Impact factor: 6.312